SEC Comment Letter for GRI Bio, Inc. (GRI) (CIK 0001824293) (GRI) — Jan 30, 2026
GRI Bio, Inc. (GRI) (CIK 0001824293)
Date: Jan. 30, 2026 · CIK: 0001824293 · Accession: 0000000000-26-001119
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293065
Letter
January 30, 2026 W. Marc Hertz, Ph.D. President and Chief Executive Officer GRI Bio, Inc. 2223 Avenida de la Playa, #208 La Jolla, CA 92037 Re:GRI Bio, Inc. Registration Statement on Form S-3 Filed January 30, 2026 File No. 333-293065 Dear W. Marc Hertz Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jessica Zhang, Esq.
Show Raw Text
January 30, 2026
W. Marc Hertz, Ph.D.
President and Chief Executive Officer
GRI Bio, Inc.
2223 Avenida de la Playa, #208
La Jolla, CA 92037
Re:GRI Bio, Inc.
Registration Statement on Form S-3
Filed January 30, 2026
File No. 333-293065
Dear W. Marc Hertz Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jessica Zhang, Esq.